Radiation + Immunotherapy for Non-Small Cell Lung Cancer
Trial Summary
The trial information does not specify if you need to stop taking your current medications. However, you must not have received steroids in doses higher than prednisone 10 mg daily within 14 days before starting Step 2 of the trial.
Research shows that hypofractionated radiation therapy (HFRT) can improve local control and shorten treatment time for inoperable non-small cell lung cancer (NSCLC). Additionally, combining radiation with immunotherapy, like PD-1 targeting drugs, may enhance the immune response against tumors.
12345Studies have shown that hypofractionated radiation therapy (HFRT) is generally well tolerated, but it may increase the risk of gastrointestinal (GI) or genitourinary (GU) side effects. More research is needed to fully understand the safety of combining HFRT with immunotherapy in lung cancer.
35678Hypofractionated radiation therapy (HFRT) is unique because it delivers higher doses of radiation over a shorter period, potentially improving local control and reducing treatment time. When combined with immunotherapy, it may enhance the immune response against tumors, offering a novel approach compared to traditional treatments.
12349Eligibility Criteria
This trial is for adults with stage II or III non-small cell lung cancer who've had prior treatments like surgery, chemo, or radiation but not within the last year. They must have proper liver and kidney function, no severe active infections, HIV under control, and can't be pregnant. People with certain blood counts and those who haven't used high-dose steroids recently can join. It's not for those with autoimmune diseases needing treatment in the past 6 months or a history of significant lung disease.Inclusion Criteria
Participant Groups
- Soft tissue sarcoma
- Extremity soft tissue sarcoma
- Soft tissue sarcoma
- Extremity soft tissue sarcoma
- Soft tissue sarcoma
- Extremity soft tissue sarcoma